返回 
加入收藏
基于群体药动学的利奈唑胺个体化给药研究进展
x
请在关注微信后，向客服人员索取文件
| 篇名： | 基于群体药动学的利奈唑胺个体化给药研究进展 |
| TITLE： | Research progress on individualized administration of linezolid based on population pharmacokinetics |
| 摘要： | 利奈唑胺是一种治疗多重耐药革兰氏阳性菌感染的抗菌药物，目前在临床广泛使用。但其在患者体内的药动学特征存在较大的个体差异，按说明书常规剂量给药较难获得最佳疗效。因此，有必要对利奈唑胺进行治疗药物监测（TDM），并利用群体药动学（PPK）和药效学原理指导和优化其抗菌治疗方案。本文总结了利奈唑胺在各种人群中的PPK变化及个体化给药研究进展，建议临床使用利奈唑胺时，应通过TDM将患者稳态血药浓度保持在2～8mg/mL；对于肝肾功能不全的患者，应适当降低利奈唑胺给药剂量，而对于肥胖、烧伤、儿童患者应适当增加利奈唑胺给药剂量，并在用药过程中提供药学监护，以促进合理用药。 |
| ABSTRACT： | Linezolid is an antibacterial agent for the treatment of multi-resistant Gram-positive bacterial infections， which is widely used in clinical practice. However， there are large individual differences in the pharmacokinetic characteristics of the drug in patients， and it is difficult to obtain the optimal therapeutic effect when the drug is administered according to the conventional dose in the instructions. Therefore， it is necessary to carry out therapeutic drug monitoring （TDM） for linezolid， and guide and optimize its antibacterial treatment plan by using population pharmacokinetics （PPK） and pharmacodynamics principles. This paper summarizes the PPK changes and the research progress of individualized administration of linezolid in various populations， and recommends that the patient’s steady-state blood concentration is kept at 2-8 mg/mL through TDM when using linezolid clinically. It is recommended to appropriately reduce the dosage for patients with liver and kidney dysfunction， appropriately increase the dosage for obese， burned and children patients， and provide pharmaceutical monitoring during the medication process to promote rational drug use. |
| 期刊： | 2023年第34卷第05期 |
| 作者： | 邱红玉；荣礼；谢梦圆；孔令提 |
| AUTHORS： | QIU Hongyu，RONG Li，XIE Mengyuan，KONG Lingti |
| 关键字： | 利奈唑胺；群体药动学；抗菌；个体化给药 |
| KEYWORDS： | linezolid； population pharmacokinetics； antibacterial； individualized administration |
| 阅读数： | 227 次 |
| 本月下载数： | 8 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
